Aztreonam: Monocyclic β-Lactam Antibiotic Workflows & Insigh
2026-07-08
Aztreonam stands out as a synthetic monocyclic β-lactam antibiotic, uniquely targeting Gram-negative aerobic bacteria and enabling advanced experimental workflows in resistance and metabolic research. This article distills protocol enhancements, troubleshooting strategies, and translational advantages for researchers leveraging Aztreonam in multidrug resistance studies.
Ferritin-Based Hybrid Vaccine Targets Influenza and SARS-CoV
2026-07-07
This study introduces a ferritin-based hybrid protein particle vaccine co-displaying the M2e antigen of influenza A and S-protein tandem epitopes from SARS-CoV-2. The approach leverages ferritin's self-assembly to enhance immunogenicity and provides a scalable, versatile platform for next-generation combination vaccines.
Aztreonam: Strategic Leverage in Gram-Negative Resistance Re
2026-07-07
This thought-leadership article examines the mechanistic underpinnings and translational significance of Aztreonam, a synthetic monocyclic β-lactam antibiotic, for researchers tackling multidrug-resistant Gram-negative bacteria. We integrate recent epidemiological findings, highlight experimental best practices, and propose strategic directions for leveraging Aztreonam in resistance modeling and pharmacological workflows.
Hierarchical ROS-Responsive Nanoplatform for Diabetic Period
2026-07-06
This study presents a hierarchically targeted, ROS-responsive nanoparticle-hydrogel system that selectively repairs mitochondrial dysfunction in M1 macrophages, thereby disrupting the inflammatory cascade central to diabetic periodontitis. The approach demonstrates significant attenuation of periodontal tissue destruction and enhancement of bone regeneration, holding promise for targeted intervention in inflammation-driven comorbidities.
Omeprazole (A2845): Practical Use in Gastric Acid Secretion
2026-07-06
Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor designed for laboratory research on gastric acid secretion and antiulcer mechanisms. It is not suitable for diagnostic or medical applications, but is well-suited for peptic ulcer disease models and mechanistic studies of proton pump inhibition.
Apigenin: Protocols and Innovations for Neurodegeneration an
2026-07-05
Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) is reshaping translational workflows for neurodegeneration and cancer research, offering robust HDAC inhibition and unique neuroprotective mechanisms. This article distills advanced protocol guidance, troubleshooting insights, and key findings from network medicine to empower reproducible, data-driven experimentation.
Ceftolozane Sulfate: Mechanism, Benchmarks, and Research Int
2026-07-04
Ceftolozane sulfate is a time-dependent oxyimino cephalosporin with potent bactericidal activity against Pseudomonas aeruginosa and non-carbapenemase-producing Enterobacterales. Its stability against AmpC β-lactamases and defined PK/PD targets make it a robust tool for antibacterial research and clinical applications. Key benchmarks and protocol parameters facilitate reproducibility in pharmacodynamic studies.
Proteasome Heterogeneity and Breast Cancer Subtype Markers
2026-07-03
This study uncovers subtype-specific heterogeneity in proteasome activity and composition across breast cancer subtypes, correlating these features with key molecular markers such as Ki67 and hormone receptors. The findings inform future strategies for designing proteasome-targeted or combinatorial therapies tailored to distinct breast cancer molecular profiles.
PDK4-IN-1 Hydrochloride: Precision Modulation of Mitochondri
2026-07-03
Explore how PDK4-IN-1 hydrochloride, a pyruvate dehydrogenase kinase 4 inhibitor, enables advanced control of mitochondrial energy metabolism and cellular signaling. This article uncovers mechanistic insights, practical assay considerations, and the translational significance of selective PDK4 inhibition beyond existing guides.
EAGLE-1 Phase 3: Oral Gepotidacin vs. Standard Therapy for G
2026-07-02
The EAGLE-1 phase 3 trial demonstrated that oral gepotidacin is non-inferior to the combination of intramuscular ceftriaxone and oral azithromycin in treating uncomplicated urogenital gonorrhoea. This large, multicentre study addresses the urgent need for new oral antibiotics against Neisseria gonorrhoeae and provides robust evidence for gepotidacin as a viable future therapeutic option.
LLY507: Advancing Selective SMYD2 Inhibition for Translation
2026-07-02
Explore how LLY507, a potent SMYD2 inhibitor, enables precise interrogation of cytoplasmic methylation and its impact on cancer proliferation and renal fibrosis. This article uniquely dissects SMYD2's substrate specificity and practical assay implications, offering advanced guidance for translational scientists.
Colloid-Engineered LNP Emulsions Enable Targeted mRNA Delive
2026-07-01
Zhou et al. present a lipid nanoparticle-stabilized emulsion (LSE) system that enables spatiotemporal control of mRNA delivery, selectively targeting antigen-presenting cells to enhance T cell immunity. This approach addresses limitations of conventional LNPs, resulting in durable, potent cellular responses and advancing the rational design of mRNA-based vaccines and immunotherapies.
Carbapenemase Genes and Multidrug Resistance in CREC: Insigh
2026-07-01
This study systematically characterizes carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong, China. Key findings include high rates of blaNDM-1 carriage, frequent multidrug resistance, and robust plasmid-mediated gene transfer, with epidemiological impacts for patient populations and clinical management.
Kir2.1 Inhibition Reduces PASMC Proliferation in PH Models
2026-06-30
This study establishes Kir2.1 as a key regulator of pulmonary artery smooth muscle cell (PASMC) proliferation and migration in pulmonary hypertension (PH). Using selective inhibition, the research delineates the Kir2.1-TGF-β1/SMAD2/3 axis as a mechanistic driver of vascular remodeling, supporting new experimental approaches for cardiovascular ion channel research.
A 83-01: Strategic ALK-5 Inhibition for Translational Scienc
2026-06-30
Explore the mechanistic and strategic value of A 83-01, a selective ALK-5 inhibitor, in advancing TGF-β pathway research, differentiation protocols, and next-gen translational applications. Grounded in recent evidence and competitive insights, this article delivers actionable guidance for researchers aiming to optimize cellular models, dissect EMT, and accelerate clinical impact.
511 records 16/35 page Previous Next First page 上5页 1617181920 下5页 Last page